Statement by Teva Pharmaceuticals on Eshoo-Barton Bill
NORTH WALES, Pa., March 17, 2009 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the leading generic pharmaceutical company, today released the following statement by Debra Barrett, Senior Vice President of Government Affairs on the introduction of a biogenerics bill by Representatives Anna Eshoo and Joe Barton:
"In this year of healthcare reform, consumers should rightfully demand better access to affordable medicines. The legislation re-introduced in the House today is clearly written to protect brand-name drugs and their innovator's government-granted monopoly at the expense of access and innovation. This bill will dampen innovation and deny Americans access to more affordable healthcare.
"Congress took a bold step in 1984 when it passed Hatch-Waxman - an effort that led to the greatest explosion of innovative medicines in history - while creating a pathway for more affordable alternatives. We hope that our policymakers will enact legislation that puts the interests of patients above the guarantee of excessive monopoly."
Teva USA is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., one of the largest generic pharmaceutical companies in the world and among the top 20 pharmaceutical companies. For more information, please visit www.tevausa.com or www.tevadc.com.
Media Contact: Denise Bradley Phone: (215) 591-8974 E-mail: Denise.Bradley@tevausa.com
CONTACT: Denise Bradley of Teva Pharmaceuticals USA, +1-215-591-8974, Denise.Bradley@tevausa.com
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: March 2009